Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Large-scale testing (Phase 3)Study completedNCT00154102
What this trial is testing

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)

Who this might be right for
Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 1,221
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Not applicableEnded earlyNCT01074333
What this trial is testing

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasm
Merck KGaA, Darmstadt, Germany 146
Testing effectiveness (Phase 2)Study completedNCT00125034
What this trial is testing

Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Neoplasm MetastasisColorectal Cancer
Merck KGaA, Darmstadt, Germany 344
Large-scale testing (Phase 3)Study completedNCT03206151
What this trial is testing

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd 520